Description: Cerivastatin (BAY-w-6228, Rivastatin) is a statin class of lipid-lowering agent used to lower cholesterol and prevent cardiovascular disease. It is a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin was marketed by Bayer A.G. in the late 1990s but was voluntarily withdrawn from the market worldwide in 2001, due to reports of fatal rhabdomyolysis. During postmarketing surveillance, 52 deaths were reported in patients using Cerivastatin, mainly from rhabdomyolysis and its resultant renal failure.

References:

[1]. Denoyelle C, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001 Aug;22(8):1139-48.

[2]. Stein E, et al. Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia. J Cardiovasc Pharmacol Ther. 1997 Jan;2(1):7-16.

Related CAS #:145599-86-6 (free acid) 143201-11-0 (sodium) 158878-47-8 (Cerivastatin lactone)

纯度：≥98%

CAS：145599-86-6